Welcome to our dedicated page for Lifevantage Corporation news (Ticker: LFVN), a resource for investors and traders seeking the latest updates and insights on Lifevantage Corporation stock.
Lifevantage Corporation Common Stock (Delaware) (symbol: LFVN) is a pioneering company in the field of nutrigenomics, a cutting-edge area of nutritional science focused on how nutrients affect gene expression to improve health and wellness. Founded on the premise that aging is inevitable but can be managed, Lifevantage offers a range of products designed to combat the effects of aging and promote overall well-being.
The company's core business involves the identification, research, development, and distribution of nutraceutical dietary supplements and skincare products. Among its flagship offerings is Protandim, a scientifically-validated dietary supplement known for its ability to reduce oxidative stress. Other notable products include the LifeVantage TrueScience anti-aging skincare line, Axio energy drink mixes, PhysIQ weight management systems, and Canine Health, a pet supplement formulated to improve the health of dogs.
Lifevantage's products are available in multiple regions, including the United States, Japan, Hong Kong, Australia, Canada, the Philippines, Mexico, Thailand, the United Kingdom, and the Netherlands. This geographical diversification helps the company reach a broad audience and sustain its growth trajectory.
Recently, Lifevantage has made significant strides in its business operations. Hundreds of independent consultants hosted virtual watch parties to kickstart the company's initiatives for 2024. The company also continues to innovate, as seen in the second quarter of fiscal 2024 results and the upcoming launch of its Evolve Compensation Plan and Rewards Circle customer loyalty program on February 1, 2024. These initiatives are designed to enhance customer satisfaction and drive business growth.
Financially, Lifevantage is committed to transparency and accountability, regularly updating investors on its performance through detailed reports and investor relations contacts. Despite the challenges posed by COVID-19, the company has maintained a resilient stance, focusing on future growth and product expansion.
Overall, Lifevantage remains a significant player in the health and wellness industry, continually advancing the science of nutrigenomics to offer effective solutions for aging and other health-related concerns.
LifeVantage Corporation (Nasdaq: LFVN) will announce its financial results for the second quarter ended December 31, 2022, on February 2, 2023, after the market closes. The company will host a conference call for investors at 2:30 p.m. MT (4:30 p.m. ET). Interested parties can call (877) 704-4453 in the U.S. or (201) 389-0920 internationally to participate. A replay will be available until February 9, 2023. Additionally, a live webcast will be accessible on the company’s Investor Relations website and archived for 30 days.
LifeVantage Corporation (Nasdaq: LFVN) announced its strategic transformation initiative, LV360, aimed at enhancing the Consultant and Customer experience. Key features include the launch of Evolve, a new compensation model, and the Rewards Circle customer loyalty program, set to debut on March 1, 2023. Over 10,000 Consultants participated in the announcement via a global broadcast. The initiative aims to strengthen market position and address evolving consumer trends with new products, enhanced e-commerce, and extensive training sessions scheduled globally. The company's focus remains on solidifying its reputation in health and wellness.
LifeVantage Corporation (Nasdaq: LFVN) has declared a quarterly cash dividend of $0.03 per share, to be distributed on December 15, 2022, to shareholders on record as of December 1, 2022. This announcement reflects the company's commitment to providing returns to its investors amidst its focus on nutrigenomics and health solutions. LifeVantage markets a range of dietary supplements, including its flagship product Protandim®, and is dedicated to research and development in natural health advancements.
LifeVantage Corporation (Nasdaq: LFVN) reported Q1 fiscal 2023 revenue of $51.8 million, a 2.7% decrease year-over-year. However, excluding foreign currency fluctuations, revenue grew 2.3%. Active accounts fell 6.7% to 153,000, with notable declines in the Americas (7.8%) and Asia/Pacific & Europe (4.1%). Net income was $0.6 million, or $0.05 per diluted share, down from $3.3 million, or $0.25 per share a year ago. The company maintains a solid balance sheet with $17.6 million cash and no debt. Fiscal 2023 guidance remains at $200-$212 million in revenue and adjusted EBITDA of $12-$14 million.
LifeVantage Corporation (Nasdaq: LFVN) will announce its Q1 financial results for the period ending September 30, 2022, on November 2, 2022, after market close. The company will host a conference call for investors at 2:30 p.m. MT (4:30 p.m. ET) on the same day. Interested parties can join the call via U.S. (855) 327-6837 or international (631) 891-4304. A replay will be available until November 9, 2022. Additionally, a live webcast will be accessible on their Investor Relations website, archived for 30 days.
LifeVantage Corporation (Nasdaq: LFVN) has announced a quarterly cash dividend of $0.03 per share, scheduled for payment on September 15, 2022, to stockholders on record as of September 2, 2022. This decision highlights the company's commitment to returning value to its shareholders. LifeVantage specializes in nutrigenomics and offers a range of products including dietary supplements and skin care solutions, while continuously focusing on innovation and growth in this sector.
LifeVantage Corporation (LFVN) reported its fourth-quarter and full-year results for fiscal 2022, revealing a 7.0% revenue decline to $50.9 million in Q4 and a 6.3% drop to $206.4 million for the full year. Active accounts decreased 8.2% to 156,000. The company experienced a net loss of $1.4 million ($0.11 per diluted share) in Q4, compared to a net income of $4.9 million ($0.35 per diluted share) in the previous year. Adjusted EBITDA was $1.7 million in Q4, significantly down from $6.6 million a year earlier. Fiscal 2023 guidance suggests revenue will range from $200 million to $212 million.
LifeVantage Corporation (Nasdaq: LFVN) will release its financial results for the fourth quarter and full fiscal year ending June 30, 2022, on August 23, 2022, after market close. A conference call for investors is scheduled at 2:30 PM MT (4:30 PM ET) on the same day. Investors can participate via phone or listen to a live webcast, with archived access available for 30 days. LifeVantage specializes in nutrigenomics, including dietary supplements and health products like Protandim® and Petandim®.
LifeVantage Corporation (Nasdaq: LFVN) hosted Activate 2022, attracting over 6,000 distributors, marking a strong return to in-person gatherings post-pandemic. The event unveiled TrueScience® Liquid Collagen, featuring a rare Ruby Red Quinoa Extract, which enhances collagen synthesis by 42% and increases antioxidant levels by up to 202%. This product aims to differentiate LifeVantage in the nutrigenomics space by activating natural collagen production.
LifeVantage Corporation (Nasdaq: LFVN) has announced a new quarterly cash dividend of $0.03 per share, set to be paid on May 31, 2022. Shareholders of record as of May 17, 2022 will be eligible for this dividend. The company is noted for its nutrigenomics focus, providing a range of health products including dietary supplements and wellness solutions. This dividend initiation is a significant move, indicating the company's commitment to returning value to its shareholders.
FAQ
What is the current stock price of Lifevantage Corporation (LFVN)?
What is the market cap of Lifevantage Corporation (LFVN)?
What does Lifevantage Corporation do?
What are some of the key products offered by Lifevantage?
In which regions are Lifevantage's products sold?
What recent achievements has Lifevantage made?
How does Lifevantage contribute to the field of nutrigenomics?
What is Protandim?
How does Lifevantage support its investors?
What challenges has Lifevantage faced recently?
Who should use Lifevantage products?
What is the Evolve Compensation Plan?
